BRPI0017596A2 - Método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente - Google Patents

Método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente

Info

Publication number
BRPI0017596A2
BRPI0017596A2 BRPI0017596A BRPI0017596A2 BR PI0017596 A2 BRPI0017596 A2 BR PI0017596A2 BR PI0017596 A BRPI0017596 A BR PI0017596A BR PI0017596 A2 BRPI0017596 A2 BR PI0017596A2
Authority
BR
Brazil
Prior art keywords
radiolabeling
chelator
administration
patient
antibody conjugated
Prior art date
Application number
Other languages
English (en)
Inventor
John E Leonard
Michael Labarre
Paul Chinn
Ronald Morena
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of BRPI0017596A2 publication Critical patent/BRPI0017596A2/pt
Publication of BRPI0017596B1 publication Critical patent/BRPI0017596B1/pt
Publication of BRPI0017596B8 publication Critical patent/BRPI0017596B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Steroid Compounds (AREA)
  • Packages (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0017596A 1999-03-01 2000-02-29 método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente BRPI0017596B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/259,337 US20020102208A1 (en) 1999-03-01 1999-03-01 Radiolabeling kit and binding assay
PCT/US2000/005061 WO2000052473A2 (en) 1999-03-01 2000-02-29 Radiolabeling kit and binding assay
BRPI0008719-0 BRPI0008719B8 (pt) 1999-03-01 2000-02-29 Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo

Publications (3)

Publication Number Publication Date
BRPI0017596A2 true BRPI0017596A2 (pt) 2011-09-27
BRPI0017596B1 BRPI0017596B1 (pt) 2015-09-01
BRPI0017596B8 BRPI0017596B8 (pt) 2023-04-25

Family

ID=22984524

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0008719-0 BRPI0008719B8 (pt) 1999-03-01 2000-02-29 Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo
BRPI0017596A BRPI0017596B8 (pt) 1999-03-01 2000-02-29 método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0008719-0 BRPI0008719B8 (pt) 1999-03-01 2000-02-29 Método para radiomarcação de um anticorpo conjugado a um quelante com 90y e ensaio de ligação para determinação da ligação percentual de um anticorpo radiomarcado à sua célula alvo

Country Status (35)

Country Link
US (2) US20020102208A1 (pt)
EP (2) EP2112512B1 (pt)
JP (1) JP4704570B2 (pt)
KR (1) KR100729247B1 (pt)
CN (1) CN1235639C (pt)
AT (1) ATE433108T1 (pt)
AU (1) AU776747B2 (pt)
BG (1) BG65690B1 (pt)
BR (2) BRPI0008719B8 (pt)
CA (2) CA2362119C (pt)
CY (2) CY1109335T1 (pt)
CZ (2) CZ303262B6 (pt)
DE (1) DE60042326D1 (pt)
DK (2) DK1192463T3 (pt)
EE (1) EE05650B1 (pt)
ES (2) ES2328100T3 (pt)
HK (1) HK1045730B (pt)
HR (1) HRP20010714B1 (pt)
HU (2) HU229627B1 (pt)
IL (1) IL145109A0 (pt)
ME (1) ME00782B (pt)
MX (1) MXPA01008837A (pt)
MY (1) MY138674A (pt)
NO (2) NO329142B1 (pt)
NZ (2) NZ513788A (pt)
PL (1) PL205780B1 (pt)
PT (2) PT1192463E (pt)
RS (1) RS51778B (pt)
RU (1) RU2251110C2 (pt)
SI (2) SI1192463T1 (pt)
SK (2) SK288096B6 (pt)
TW (1) TWI294969B (pt)
UA (1) UA78484C2 (pt)
WO (1) WO2000052473A2 (pt)
ZA (1) ZA200106943B (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6107090A (en) 1996-05-06 2000-08-22 Cornell Research Foundation, Inc. Treatment and diagnosis of prostate cancer with antibodies to extracellur PSMA domains
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90
US6207858B1 (en) * 1999-03-03 2001-03-27 Idec Pharmaceuticals Corporation Regioselective synthesis of DTPA derivatives
EP1918305A1 (en) 1999-08-11 2008-05-07 Biogen Idec Inc. New clinical parameters for determining hematologic toxicity prior to radioimmunotherapy
JP4202127B2 (ja) 2000-10-02 2008-12-24 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド アンタゴニスト抗ｃｄ４０抗体を用いるｂ細胞悪性腫瘍の治療方法
JP2005500018A (ja) * 2001-04-02 2005-01-06 アイデック ファーマスーティカルズ コーポレイション ＧｎＴＩＩＩと同時発現する組換え抗体
ATE535258T1 (de) 2001-06-01 2011-12-15 Cornell Res Foundation Inc Modifizierte antikörper gegen prostata- spezifisches membranantigen und ihre verwendungen
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP2005527474A (ja) 2001-09-20 2005-09-15 コーネル リサーチ ファンデーション インコーポレーテッド 前立腺特異的膜抗原に特異的な結合剤を用いて、皮膚障害を治療するかまたは防止するための方法および組成物
DE60323677D1 (de) 2003-01-10 2008-10-30 Millennium Pharm Inc Verfahren zur bestimmung des wiederauftretens von prostata krebs
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DE602004015454D1 (de) * 2003-06-25 2008-09-11 Peregrine Pharmaceuticals Inc Verfahren und vorrichtung zur kontinuierlichen radioaktiven markierung von proteinen im grossen massstab
EP2236172A1 (en) 2003-11-04 2010-10-06 Novartis Vaccines and Diagnostics, Inc. Combination therapy comprising anti-CD20 and anti-CD40 antibodies for the treatment of B cell-related cancers
EP2243491A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-CD40 monoclonal antibodies for treatment of chronic lymphocytic leukemia
DK1684805T3 (da) 2003-11-04 2010-10-04 Novartis Vaccines & Diagnostic Anvendelse af antagonist anti-CD40-monoklonale antistoffer til behandling af multipel myeloma
SG148143A1 (en) 2003-11-04 2008-12-31 Novartis Vaccines & Diagnostic Antagonist anti-cd40 monoclonal antibodies and methods for their use
PL1680141T3 (pl) 2003-11-04 2011-04-29 Novartis Vaccines & Diagnostics Inc Sposoby leczenia guzów litych wykazujących ekspresję antygenu powierzchniowego CD40
PL1889065T3 (pl) 2005-05-18 2013-12-31 Novartis Ag Metody diagnostyki i leczenia chorób posiadających składnik autoimmunologiczny i/lub zapalny
AU2006269458B2 (en) 2005-07-08 2012-11-08 Biogen Ma Inc. Sp35 antibodies and uses thereof
WO2007023408A2 (en) * 2005-08-25 2007-03-01 Koninklijke Philips Electronics N.V. 4d image-based planning methods and apparatus for targeted therapy
ES2548518T3 (es) * 2005-11-23 2015-10-19 Ventana Medical Systems, Inc. Conjugado molecular
US8945564B2 (en) 2006-04-21 2015-02-03 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
US9382327B2 (en) 2006-10-10 2016-07-05 Vaccinex, Inc. Anti-CD20 antibodies and methods of use
RU2448973C2 (ru) * 2006-11-10 2012-04-27 Альфаптозе ГмбХ Применение соединений три-замещенного глицерина для лечения радиационных поражений
CZ300074B6 (cs) * 2006-12-20 2009-01-21 Azacycles S. R. O. Inteligentní trífunkcní makrokonjugáty a farmaceutický nebo diagnostický prostredek s jejich obsahem
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
ES2464815T3 (es) 2007-01-09 2014-06-04 Biogen Idec Ma Inc. Anticuerpos SP35 y usos de éstos
DK2234600T3 (da) * 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
DK2982695T3 (da) 2008-07-09 2019-05-13 Biogen Ma Inc Sammensætninger, der omfatter antistoffer mod lingo eller fragmenter deraf
JP5475774B2 (ja) 2008-07-16 2014-04-16 インスティテュート フォー リサーチ イン バイオメディシン ヒトサイトメガロウイルス中和抗体およびその使用
US8124093B2 (en) 2008-07-16 2012-02-28 Institute For Research In Biomedicine Human cytomegalovirus neutralizing antibodies and use thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
ES2662519T3 (es) 2008-07-25 2018-04-06 Institute For Research In Biomedicine Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos
NZ592054A (en) 2008-10-13 2013-06-28 Inst Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
US20120003235A1 (en) 2008-12-31 2012-01-05 Biogen Idec Ma Inc. Anti-lymphotoxin antibodies
WO2011092593A2 (en) 2010-01-20 2011-08-04 Institute For Research In Biomedicine Hiv-1 neutralizing antibodies and uses thereof
US8911736B2 (en) 2010-03-12 2014-12-16 Genzyme Corporation Combination therapy for treating breast cancer
ES2739503T3 (es) 2010-07-09 2020-01-31 Bioverativ Therapeutics Inc Moléculas de cadena simple procesables y polipéptidos producidos usándolas
DK2601214T3 (en) 2010-08-06 2018-02-05 Genzyme Corp VEGF ANTAGONIST COMPOSITIONS AND APPLICATIONS THEREOF
BR112013003278B1 (pt) 2010-08-13 2019-06-18 Prosugar Indústria E Comércio S.A. Método de redução da coloração de açúcar, processo de produção de açúcar com baixacoloração, composição, kit e usos de três componentes ou de dois componentes
US20140142049A1 (en) 2011-03-11 2014-05-22 Zhiqiang Jia Pegylated apelin and uses thereof
CA2841551C (en) 2011-07-18 2020-07-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
UY34317A (es) 2011-09-12 2013-02-28 Genzyme Corp Anticuerpo antireceptor de célula T (alfa)/ß
EP2793947B1 (en) 2011-12-23 2021-02-03 Innate Pharma Enzymatic conjugation of polypeptides
EP2828293B1 (en) 2012-03-20 2017-10-25 Humabs Biomed S.A. Antibodies that neutralize rsv, mpv and pvm and uses thereof
JP6779012B2 (ja) 2012-03-28 2020-11-04 サノフイＳａｎｏｆｉ ブラジキニンｂ１受容体リガンドに対する抗体
WO2013175276A1 (en) 2012-05-23 2013-11-28 Argen-X B.V Il-6 binding molecules
RU2522203C2 (ru) * 2012-06-26 2014-07-10 Василий Александрович Ишутин Способ контроля стерилизации материалов и изделий
US10132799B2 (en) 2012-07-13 2018-11-20 Innate Pharma Screening of conjugated antibodies
US9790268B2 (en) 2012-09-12 2017-10-17 Genzyme Corporation Fc containing polypeptides with altered glycosylation and reduced effector function
US10036010B2 (en) 2012-11-09 2018-07-31 Innate Pharma Recognition tags for TGase-mediated conjugation
IL289918B2 (en) 2013-03-11 2025-07-01 Genzyme Corp Site-specific antibody-drug conjugation through glycoengineering
WO2014165216A1 (en) 2013-03-12 2014-10-09 The Trustees Of The University Of Pennsylvania Diagnosing and treating cancer
EP2968582B1 (en) 2013-03-15 2020-07-01 Innate Pharma Solid phase tgase-mediated conjugation of antibodies
EP3010547B1 (en) 2013-06-20 2021-04-21 Innate Pharma Enzymatic conjugation of polypeptides
CN105517577A (zh) 2013-06-21 2016-04-20 先天制药公司 多肽的酶促偶联
RU2558929C2 (ru) * 2013-08-08 2015-08-10 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт кардиологии" (НИИ Кардиологии) СПОСОБ ОПРЕДЕЛЕНИЯ СВЯЗЫВАНИЯ РАДИОФАРМПРЕПАРАТА НА ОСНОВЕ ЦИПРОФЛОКСАЦИНА, МЕЧЕННОГО 99mTc C БАКТЕРИЯМИ
SG10201710013RA (en) 2013-08-13 2018-01-30 Sanofi Sa Antibodies to plasminogen activator inhibitor-1 (pai-1) and uses thereof
US11052177B2 (en) 2013-09-06 2021-07-06 The Trustees Of The University Of Pennsylvania Antimicrobial polymer layers
JP6535675B2 (ja) 2013-10-02 2019-06-26 メディミューン，エルエルシー 抗ａ型インフルエンザ抗体の中和及びその使用
CN106030304B (zh) * 2014-02-27 2018-02-06 得克萨斯大学体系董事会 用于分离外来体的方法和组合物
US10995148B2 (en) 2014-03-19 2021-05-04 Genzyme Corporation Site-specific glycoengineering of targeting moieties
EP3122780B1 (en) 2014-03-27 2022-03-09 Bird Rock Bio, Inc. Antibodies that bind human cannabinoid 1 (cb1) receptor
CN113563462B (zh) 2014-07-15 2024-08-13 免疫医疗有限责任公司 中和抗乙型流感抗体及其用途
WO2016014613A1 (en) 2014-07-22 2016-01-28 The Trustees Of The University Of Pennsylvania Compositions and methods for cancer immunotherapy
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
PT3204425T (pt) 2014-10-09 2020-12-18 Genzyme Corp Conjugados anticorpo fármaco glicomanipulados
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
LT3220947T (lt) 2014-11-18 2020-12-28 Humabs Biomed S.A. Antikūnai, galintys neutralizuoti pasiutligės virusą ir kitus lisavirusus bei jų panaudojimas
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
MX2018001217A (es) 2015-07-30 2018-09-12 Univ Pennsylvania Alelos polimorficos de nucleotidos individuales del gen humano dp-2 para la deteccion de la susceptibilidad a la inhibicion del crecimiento del cabello por pgd2.
WO2017040708A1 (en) 2015-08-31 2017-03-09 Fruition Marketing, Llc Consumer usable device with redeemable member
WO2017048902A1 (en) 2015-09-15 2017-03-23 Board Of Regents, The University Of Texas System T-cell receptor (tcr)-binding antibodies and uses thereof
JP2019502651A (ja) 2015-09-30 2019-01-31 バード・ロック・バイオ・インコーポレイテッドＢｉｒｄ Ｒｏｃｋ Ｂｉｏ， Ｉｎｃ． ヒトカンナビノイド１（ｃｂ１）受容体に結合する抗体
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
SG11201805001UA (en) 2016-01-13 2018-07-30 Medimmune Llc Method of treating influenza a
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
SG11201909265QA (en) 2017-04-19 2019-11-28 Inst Res Biomedicine Plasmodium sporozoite npdp peptides as vaccine and target novel malaria vaccines and antibodies binding to
US11427634B2 (en) 2017-05-05 2022-08-30 Vaccinex, Inc. Human anti-semaphorin 4D antibody
CN111032089A (zh) 2017-07-19 2020-04-17 霍夫曼技术公司 用于治疗应激相关障碍的组合物
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
CN109550061A (zh) * 2017-09-26 2019-04-02 南京江原安迪科正电子研究发展有限公司 一种用于放射性核素标记抗体的试剂盒及应用
RU2700584C1 (ru) * 2018-12-13 2019-09-18 Общество С Ограниченной Ответственностью "Апто-Фарм" Способ оценки сродства олигонуклеотида
WO2020132091A2 (en) 2018-12-19 2020-06-25 Humabs Biomed Sa Antibodies that neutralize hepatitis b virus and uses thereof
WO2020206063A1 (en) 2019-04-03 2020-10-08 Genzyme Corporation Anti-alpha beta tcr binding polypeptides with reduced fragmentation
WO2021042000A1 (en) 2019-08-29 2021-03-04 Vir Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
US11879004B2 (en) 2020-02-28 2024-01-23 Genzyme Corporation Modified binding polypeptides for optimized drug conjugation
EP4164745A1 (en) 2020-06-11 2023-04-19 Vaccinex, Inc. Use of cxcl13 binding molecules to promote peripheral nerve regeneration
US20240092872A1 (en) 2021-01-26 2024-03-21 Vir Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
TW202430561A (zh) 2022-09-30 2024-08-01 法商賽諾菲公司 抗cd28抗體
EP4608859A1 (en) 2022-10-25 2025-09-03 Ablynx N.V. Glycoengineered fc variant polypeptides with enhanced effector function
US12195546B2 (en) 2022-12-19 2025-01-14 Sanofi CD28/OX40 bispecific antibodies
WO2025177185A1 (en) * 2024-02-20 2025-08-28 Janssen Biotech, Inc. Materials and methods for biologic affinity analysis
WO2025257408A1 (en) 2024-06-14 2025-12-18 Sanofi Treatment of solid organ transplant subjects with cd28/ox40 bispecific antibodies
WO2026024319A1 (en) 2024-07-23 2026-01-29 Bird Rock Bio Sub, Inc. Treatment of obesity and obstructive sleep apnea

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3994966A (en) * 1972-09-28 1976-11-30 The Board Of Trustees Of The Leland Stanford Junior University Chelating agents
US4043998A (en) * 1974-10-09 1977-08-23 The Board Of Trustees Of The Leland Stanford Junior University 1-(P-benzenediazonium)-ethylenediamine tetraacetic acid
US4315851A (en) * 1978-12-29 1982-02-16 Kureha Kagaku Kogyo Kabushiki Kaisha Pharmaceutical composition having antitumor activity
US4460561A (en) * 1980-03-03 1984-07-17 Goldenberg M David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4460559A (en) * 1980-03-03 1984-07-17 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4331647A (en) * 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4361544A (en) * 1980-03-03 1982-11-30 Goldenberg Milton David Tumor localization and therapy with labeled antibodies specific to intracellular tumor-associated markers
US4444744A (en) * 1980-03-03 1984-04-24 Goldenberg Milton David Tumor localization and therapy with labeled antibodies to cell surface antigens
US4622420A (en) * 1980-03-18 1986-11-11 The Regents Of The University Of California Chelating agents and method
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
JPS5982222U (ja) * 1982-11-26 1984-06-02 松井　三郎 眼鏡
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4707352A (en) 1984-01-30 1987-11-17 Enzo Biochem, Inc. Method of radioactively labeling diagnostic and therapeutic agents containing a chelating group
US4636380A (en) 1984-04-23 1987-01-13 Wong Dennis W Novel physiologic chemical method of labeling protein substances with the radionuclides of indium
US4634586A (en) * 1984-05-21 1987-01-06 The Board Of Trustees Of The Leland Stanford Junior University Reagent and method for radioimaging leukocytes
US4722892A (en) * 1984-08-31 1988-02-02 Meares Claude F Monoclonal antibodies against metal chelates
US4824986A (en) * 1985-04-26 1989-04-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Metal chelate protein conjugate
US4735210A (en) * 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5101827A (en) * 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US4926869A (en) * 1986-01-16 1990-05-22 The General Hospital Corporation Method for the diagnosis and treatment of inflammation
CA1266344A (en) * 1986-02-14 1990-02-27 Miki Kurami High molecular compounds having amino groups, and their utilization
EP0529645B1 (en) * 1986-09-05 1996-10-23 GANSOW, Otto A. Process for the preparation of backbone polysubstituted chelates
US4831175A (en) * 1986-09-05 1989-05-16 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5246692A (en) * 1986-09-05 1993-09-21 The United States Of America As Represented By The Secretary Of Health And Human Services Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5099069A (en) 1986-09-05 1992-03-24 Gansow Otto A Backbone polysubstituted chelates for forming a metal chelate-protein conjugate
US5034223A (en) * 1986-10-09 1991-07-23 Neorx Corporation Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU619218B2 (en) 1987-11-06 1992-01-23 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5130118A (en) 1987-11-06 1992-07-14 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US5217704A (en) 1987-11-06 1993-06-08 Abbott Laboratories Methods and materials for the preparation of metal labelled antibody solutions
US4978745A (en) 1987-11-23 1990-12-18 Centocor, Inc. Immunoreactive heterochain antibodies
US4861579A (en) * 1988-03-17 1989-08-29 American Cyanamid Company Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies
US4975369A (en) 1988-04-21 1990-12-04 Eli Lilly And Company Recombinant and chimeric KS1/4 antibodies directed against a human adenocarcinoma antigen
US4923985A (en) * 1988-05-25 1990-05-08 The United States Of America As Represented By The Department Of Health & Human Services Process for synthesizing macrocyclic chelates
EP0416033B1 (en) * 1988-05-25 1996-03-06 THE UNITED STATES OF AMERICA as represented by the Secretary United States Department of Commerce Macrocyclic chelates and methods of use thereof
US5059518A (en) * 1988-10-20 1991-10-22 Coulter Corporation Stabilized lyophilized mammalian cells and method of making same
CA2010511A1 (en) 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US5376356A (en) * 1989-03-14 1994-12-27 Neorx Corporation Imaging tissue sites of inflammation
US5162115A (en) * 1989-05-09 1992-11-10 Pietronigro Dennis D Antineoplastic solution and method for treating neoplasms
US5460785A (en) 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5124471A (en) * 1990-03-26 1992-06-23 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Bifunctional dtpa-type ligand
US5219556A (en) * 1990-07-09 1993-06-15 Mallinckrodt Medical, Inc. Stabilized therapeutic radiopharmaceutical complexes
US5009069A (en) * 1990-08-24 1991-04-23 Molini Alberto E Method of recovering energy from ocean water
GB9022543D0 (en) * 1990-10-17 1990-11-28 Wellcome Found Antibody production
JPH06501705A (ja) 1990-11-05 1994-02-24 ブリストル−マイアーズ　スクイブ　カンパニー 抗−腫瘍抗体及び生物学的活性剤の組合せによる相乗治療
US5208008A (en) * 1990-11-14 1993-05-04 University Of Pittsburgh Regioselective chemical modification of monoclonal antibodies
IL100626A0 (en) * 1991-01-11 1992-09-06 Cryopharm Corp A method of forming dry cells,diagnostic panels containing the same and diagnostic methods utilizing the same
US5403573A (en) * 1992-04-23 1995-04-04 The Curators Of The University Of Missouri Radiolabeled protein composition and method for radiation synovectomy
US5541287A (en) 1992-06-09 1996-07-30 Neorx Corporation Pretargeting methods and compounds
US5716596A (en) 1992-06-23 1998-02-10 Diatide, Inc. Radioactively labeled somatostatin-derived peptides for imaging and therapeutic uses
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
EP1005870B1 (en) * 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5736137A (en) 1992-11-13 1998-04-07 Idec Pharmaceuticals Corporation Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
US5650134A (en) 1993-01-12 1997-07-22 Novartis Ag (Formerly Sandoz Ltd.) Peptides
US5595721A (en) * 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
IL113610A0 (en) * 1994-06-03 1995-08-31 Immunomedics Inc A method of radiolabeling a protein, radiolabeled proteins prepared thereby and diagnostic kits containing the same
US5686578A (en) 1994-08-05 1997-11-11 Immunomedics, Inc. Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotype
US5728369A (en) 1994-10-05 1998-03-17 Immunomedics, Inc. Radioactive phosphorus labeling of proteins for targeted radiotherapy
US5874540A (en) 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
US5942210A (en) 1994-11-15 1999-08-24 Cytogen Corporation Methods for lyoprotecting a macromolecule using tricine
US5830431A (en) 1995-06-07 1998-11-03 Mallinckrodt Medical, Inc. Radiolabeled peptide compositions for site-specific targeting
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US20020102208A1 (en) * 1999-03-01 2002-08-01 Paul Chinn Radiolabeling kit and binding assay
MY133346A (en) * 1999-03-01 2007-11-30 Biogen Inc Kit for radiolabeling ligands with yttrium-90

Also Published As

Publication number Publication date
BRPI0008719A (pt) 2001-12-26
JP4704570B2 (ja) 2011-06-15
HRP20010714B1 (hr) 2009-01-31
HUP1300275A2 (en) 2002-11-28
BRPI0017596B1 (pt) 2015-09-01
ME00782B (me) 2012-03-20
KR100729247B1 (ko) 2007-06-15
DE60042326D1 (de) 2009-07-16
SK288096B6 (sk) 2013-07-02
PL352531A1 (en) 2003-08-25
IL145109A0 (en) 2002-06-30
US20050169838A1 (en) 2005-08-04
MY138674A (en) 2009-07-31
CA2742153A1 (en) 2000-09-08
EP2112512A2 (en) 2009-10-28
EP2112512A3 (en) 2009-12-16
RU2251110C2 (ru) 2005-04-27
EE200100465A (et) 2002-10-15
PL205780B1 (pl) 2010-05-31
US20020102208A1 (en) 2002-08-01
ZA200106943B (en) 2002-11-22
CN1345417A (zh) 2002-04-17
WO2000052473A9 (en) 2001-03-08
CY1109335T1 (el) 2014-07-02
TWI294969B (pt) 2008-03-21
NZ513788A (en) 2004-03-26
NO330705B1 (no) 2011-06-20
HU230516B1 (hu) 2016-10-28
NO329142B1 (no) 2010-08-30
CA2362119C (en) 2012-12-11
MXPA01008837A (es) 2002-05-14
CY1116265T1 (el) 2017-02-08
US7608241B2 (en) 2009-10-27
PT1192463E (pt) 2009-09-10
BG65690B1 (bg) 2009-06-30
KR20020021772A (ko) 2002-03-22
CA2742153C (en) 2015-04-14
DK2112512T3 (en) 2014-12-15
BRPI0017596B8 (pt) 2023-04-25
CZ20013126A3 (cs) 2002-07-17
BRPI0008719B1 (pt) 2015-07-21
EE05650B1 (et) 2013-04-15
NZ530868A (en) 2005-12-23
BG105957A (en) 2002-08-30
BRPI0008719B8 (pt) 2021-07-06
EP2112512B1 (en) 2014-11-19
CA2362119A1 (en) 2000-09-08
HK1045730A1 (en) 2002-12-06
CZ306959B6 (cs) 2017-10-11
AU3505200A (en) 2000-09-21
WO2000052473A3 (en) 2002-01-31
NO20014245L (no) 2001-10-31
HUP0202522A3 (en) 2011-03-28
HRP20010714A2 (en) 2003-02-28
PT2112512E (pt) 2015-01-13
WO2000052473A2 (en) 2000-09-08
JP2002538179A (ja) 2002-11-12
EP1192463B1 (en) 2009-06-03
ES2526723T3 (es) 2015-01-14
HK1045730B (zh) 2006-08-18
SI2112512T1 (sl) 2015-02-27
AU776747B2 (en) 2004-09-23
SK287745B6 (sk) 2011-08-04
ES2328100T3 (es) 2009-11-10
NO20100717L (no) 2001-10-31
SK12162001A3 (sk) 2002-12-03
CN1235639C (zh) 2006-01-11
EP1192463A2 (en) 2002-04-03
YU61601A (sh) 2004-07-15
CZ303262B6 (cs) 2012-07-04
RS51778B (sr) 2011-12-31
HUP0202522A2 (hu) 2002-11-28
SI1192463T1 (sl) 2009-10-31
ATE433108T1 (de) 2009-06-15
NO20014245D0 (no) 2001-08-31
HK1131208A1 (en) 2010-01-15
DK1192463T3 (da) 2009-10-05
HU229627B1 (en) 2014-03-28
UA78484C2 (en) 2007-04-10

Similar Documents

Publication Publication Date Title
BRPI0017596A2 (pt) Método para radiomarcação de um anticorpo conjugado a um quelante com 111in para administração a um paciente
BRPI9912227B8 (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
BRPI0210579B8 (pt) anticorpo e composição farmacêutica
ATE382370T1 (de) Antikörper-serumprotein hybride
CR20150350A (es) Proceso para preparar conjugados de anticuerpo y maytansinoide
BR0315161A (pt) Anticorpo isolado, polinicleotìdeo isolado, vetor, célula hospedeira, método de produzir um anticorpo, e, composição
PL345845A1 (en) Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
WO2001085203A3 (en) Therapeutic method and composition utilizing antigen-antibody complexation and presentation by dendritic cells
ATE423220T1 (de) Testverfahren für verbindungen die frühzeitige translations beendigung und nonsense rns decay hemmen
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
CA2366514A1 (en) Diagnostic and therapeutic use of antibodies against the urokinase receptor
BR0211697A (pt) Marcador de câncer e usos deste na diagnose de câncer
DE60014064D1 (de) Einetenascin-c isoform als marker für neoplasmen
WO2001057207A3 (en) Compositions and methods for the therapy and diagnosis of ovarian cancer
AR029540A1 (es) COMPOSICIONES Y METODOS PARA EL DIAGNoSTICO Y LA TERAPIA DE CA NCER DE PULMoN
ATE414904T1 (de) Verfahren zum testen des oxidiertes-ldl-beta-2- glycoprotein-i-komplexes in vivo
ATE308555T1 (de) Tumorsuppressormoleküle und nutzungsverfahren
BR9815776A (pt) Anticorpos monoclonais anti-tag-72 humanizados com alta afinidade

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 01/09/2015, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/02/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: REF. RPI 2330 DE 01/09/2015 QUANTO AO PRAZO DE VALIDADE. (PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/02/00, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO )

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/02/2020